SignalXSignalX

MDGL MADRIGAL PHARMACEUTICALS, INC.

Q3 2025 10-Q
Filed: Nov 4, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
MADRIGAL PHARMACEUTICALS, INC. Overview

MADRIGAL PHARMACEUTICALS, INC. (MDGL) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

  • • Revenue $287.3M Q3 2025 vs $62.2M Q3 2024, up 362% due to increased Rezdiffra demand
  • • Operating loss stable: $(114.0)M Q3 2025 vs $(116.3)M Q3 2024, 2% improvement
+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$287M

Net Income

-$114M

Operating Margin

-39.7%

Net Margin

-39.8%

ROE

-18.2%

Total Assets

$1.4B

Source: XBRL data from MADRIGAL PHARMACEUTICALS, INC. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on MADRIGAL PHARMACEUTICALS, INC.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.